RIGL's JAK2 inhibitor for RA in conjunction with SK failed in ph3 today. One less competitor for INCY, which is felt to potentially have the best in class drug since it only has to be taken once a day orally and has good toxicity profile in ph2
Accrual for Seamless has been slow, but should now accelerate as more centers have been added. The 2nd DMSB review was favorable. DMSB for futility occurs after 212 patients have been enrolled and that should be within the year, and will add value if positive.. Follow up on the MDS data would be well presented in the context of ASCO in mid May, but may be sooner. Still a lot of pluses for a biotech with a tiny market cap and the potential for a big pop with any favorable development.